ClinVar Miner

Submissions for variant NM_000049.4(ASPA):c.876_879del (p.Glu293fs) (rs766720790)

Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 5
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Counsyl RCV000409212 SCV000487300 likely pathogenic Spongy degeneration of central nervous system 2016-11-11 criteria provided, single submitter clinical testing
Laboratory for Molecular Medicine, Partners HealthCare Personalized Medicine RCV000409212 SCV000711750 likely pathogenic Spongy degeneration of central nervous system 2016-07-13 criteria provided, single submitter clinical testing The p.Glu293fs variant in ASPA has been reported in 3 individuals with Canavan d isease, including at least one compound heterozygote (Kaul 1996). This variant h as been identified in 1/66340 of European chromosomes by the Exome Aggregation C onsortium (ExAC, In vitro assays suggest that t his variant abolished ASPA protein activity (Kaul 1996); however, these types of assays may not accurately represent biological function. This variant is predic ted to cause a frameshift, which alters the protein?s amino acid sequence beginn ing at position 293 and leads to a premature termination codon 8 amino acids dow nstream. This termination codon occurs within the last exon and is more likely t o escape nonsense mediated decay (NMD) and result in a truncated protein. In sum mary, although additional studies are required to fully establish its clinical s ignificance, the p.Glu293fs variant is likely pathogenic.
Invitae RCV000409212 SCV001230214 pathogenic Spongy degeneration of central nervous system 2020-06-29 criteria provided, single submitter clinical testing This sequence change results in a premature translational stop signal in the ASPA gene (p.Glu293Leufs*8). While this is not anticipated to result in nonsense mediated decay, it is expected to disrupt the last 21 amino acids of the ASPA protein. This variant is present in population databases (rs766720790, ExAC 0.002%). This variant has been observed in an individual with Canavan disease (PMID: 8659549). In at least one individual the data is consistent with the variant being in trans (on the opposite chromosome) from a pathogenic variant. ClinVar contains an entry for this variant (Variation ID: 371665). This variant is also known as 876 delAGAA in the literature. This variant has been reported to substantially reduce the enzymatic activity of the ASPA protein in cell culture (PMID: 8659549). This variant disrupts the p.Ala305 amino acid residue in ASPA. Other variant(s) that disrupt this residue have been determined to be pathogenic (PMID: 8023850, 22850825, 10909858, 16217711). This suggests that this residue is clinically significant, and that variants that disrupt this residue are likely to be disease-causing. For these reasons, this variant has been classified as Pathogenic.
Women's Health and Genetics/Laboratory Corporation of America, LabCorp RCV001328425 SCV001519548 pathogenic Canavan Disease, Familial Form 2021-03-13 criteria provided, single submitter clinical testing Variant summary: ASPA c.876_879delAGAA (p.Glu293LeufsX8) results in a premature termination codon, predicted to cause a truncation of the encoded protein or absence of the protein due to nonsense mediated decay, which are commonly known mechanisms for disease. The variant allele was found at a frequency of 8e-06 in 251438 control chromosomes. c.876_879delAGAA has been reported in the literature in individuals affected with Canavan Disease (example, Kaul_1996, Zeng_2002). These data indicate that the variant is likely to be associated with disease. At least one publication reports experimental evidence evaluating an impact on protein function. The most pronounced variant effect results in undetectable ASPA enzyme activity in-vitro (example, Kaul_1996). Four clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014 without evidence for independent evaluation. All laboratories classified the variant as pathogenic/likely pathogenic. Based on the evidence outlined above, the variant was classified as pathogenic.
Natera, Inc. RCV000409212 SCV001190706 pathogenic Spongy degeneration of central nervous system 2019-05-20 no assertion criteria provided clinical testing

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.